PRELUDE THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
PRELUDE THERAPEUTICS INC. - More news...
PRELUDE THERAPEUTICS INC. - More news...
- Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
- Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
- Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
- Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
- Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
- Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
- Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
- Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
- Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
- Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
- Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
- Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
- Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
- Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
- Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
- Prelude Therapeutics Announces $25 Million Private Placement
- Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
- Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
- Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
- Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
- Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- Prelude Therapeutics To Participate in Jefferies Healthcare Conference
- Prelude Therapeutics Announces Pricing of Public Offering
- Prelude Therapeutics Announces Launch of Proposed Public Offering
- Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
- Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
- Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
